#1ResMed ResMed Investor Day September 8, 2021#2Forward Looking Statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com). In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates", "believes", "estimates", “predicts", "potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology. ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements. O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 2#3Today's Agenda 1:30 PM Welcome and Opening Remarks Amy Wakeham VP, IR and Corporate Communications Transforming Care as the World-Leading Digital Health Company Mick Farrell Chief Executive Officer Global Corporate Strategy Hemanth Reddy Chief Strategy Officer Pioneering the Future of Sleep Jim Hollingshead President, Sleep and Respiratory Care Business Software as a Service (SaaS) 3:10 PM Break 3:25 PM Leadership in Digital Health Technology Bobby Ghoshal President, SaaS; Chief Technology Officer Driving Operational Excellence Rob Douglas President and Chief Operating Officer Financial Strategy Brett Sandercock Chief Financial Officer Closing Remarks Mick Farrell Chief Executive Officer Bobby Ghoshal President, SaaS; Chief Technology Officer 4:15 PM Q&A Session 2:40 PM Q&A Session 5:00 PM Event End O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 3#4Transforming Care as the World-Leading Digital Health Company Mick Farrell | Chief Executive Officer ResMed#5Key messages O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Positioned to continue winning in large, underserved respiratory medical markets with a patient-centric approach, unique ResMedian culture, and 30+ years of cutting-edge innovation 2 Leading the market in digital health - continue to disrupt and reinvent the medical device industry with cloud-connected devices, market-leading software solutions, and innovative analytics 3 Transforming out-of-hospital care at scale leveraging integrated healthcare models and partnerships to provide top-quality care at lower-acuity and people-friendly environments 4 Executing ResMed 2025 strategy to improve 250 million lives in out-of-hospital care by helping people breathe better, sleep better, and live better lives: all driving stakeholder value 5#6ResMed snapshot | The global leader in connected and digital health Key Statistics Headquarters San Diego, CA 12% 12% Founded FY21 revenue 1989 Revenue Revenue $3.2B 38% by business FY 2021 50% 35% by region FY 2021 53% Market cap 1 ~$42B Countries served 140+ Total employees ~8,000 Devices ■ Masks & Other ■ OOH SaaS ■ U.S., Canada, and Latin America ■ Europe, Asia, and Other ■U.S. SaaS Our businesses Sleep Apnea Delivering a market-leading patient experience through innovative solutions that lower overall costs for treating sleep apnea patients and improve clinical outcomes by leveraging global digital health solutions. Respiratory Care Improving the lives of patients with COPD, asthma, and other key chronic respiratory diseases on their healthcare journey - lowering costs, preventing hospitalization, and creating end-to-end care solutions Software as a Service (SaaS) Providing a network out-of-hospital healthcare SaaS management solutions that help providers deliver more personalized care, measurable results, and improved health outcomes across large populations 1As of 8/31/2021 © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 6#7Continuing our journey as the market pioneer and leading innovator Where We Were 1989 - 2005 World's leader in air pressure masks: innovation in anthropometrics, mask design, and material technology for patient care 2005-2014 World's leader in flow generators + leader in masks: innovation for the smallest, quietest, most comfortable, and most consumer-friendly devices 2014+ World's leader in digital health + leader in flow generators + leader in masks: Revolutionizing the respiratory medical market with connected devices and digital solutions. Where We Are Release of next generation AirSense11 and next gen AirView and my Air 2.0 Global leader in digital end-to-end solutions for Sleep and Respiratory Care (sleep apnea, COPD and asthma), including ventilation; future growth opportunities with HFT and Propeller Investments in AI/ML/MI to accelerate digital innovation; catalyzing adoption of digital health technologies Expansion of SaaS business through organic growth, partnerships, and other strategic acquisitions Where We're Going Improve 250 million lives in out-of-hospital (OOH) care in 2025 Develop even smaller, quieter, more comfortable, more connected, and more intelligent devices Unlock value from digital health solutions to drive even better outcomes for patients, physicians, providers, healthcare systems, and communities Leverage our assets, capabilities, and leadership in digital health to unlock even richer degrees of commercial innovation models Revolutionizing the medtech industry with digital health solutions © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 7#8Premier global provider of sleep and respiratory care therapy solutions. -65% of revenue from U.S., Canada, and Latin America ResMed offices ResMed HQ -35% of revenue from Europe, Asia, and Other Serving 140+ countries worldwide; growing our global market footprint and leadership O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 8#9Delivering results through ResMedian culture We are... Key focus areas . Drive our global culture and people strategy Leaders Team players Innovative Customer obsessed Inclusive • - Appointed Vered Keisar as Chief People Officer in March 2021 Invest in our people - - - Multiple learning programs to enhance organizational capability and provide our people the opportunity to investment in their own professional and career growth Global technology infrastructure allowing 8,000 ResMedians to work seamlessly serving customers Flexible@ResMed: creating a new flexible work culture including home, in-person and hybrid office Foster an environment of responsiveness - — Regular 'pulse' surveys with best-in-class response rates, and clear actions based on feedback Enable and empower all ResMedians to strive toward positive change and outcomes, starting with themselves, their teams, and sharing best practices with the global team Grow our culture of diversity and inclusion - - - Dedicated D&I Director, responsible for leading our global D&I initiatives with a program that we call BIDS: belonging, inclusion, and diversity for success at ResMed Formed many networks of employee resource groups (ERGS) - including Black Excellence, LEAN, Respect, HOLA!, RISE, Parents, ASPIRE, Veterans as well as 'mosaic'-location-based ERGS Driving success and continuous improvement in gender equality: ~53% of ResMedians are female, >30% of senior executives are female; 50% of non-executive directors are female Our unique culture has driven strong results... TSR (NYSE shares as of 6/30/2021): 1-yr 29% ☐ 3-yr 146% ▪ 5-yr 318% ☐ © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 9#10ESG has always been in our DNA Environmental Environmental improvements from 2018-2020 14% In GHG emissions at San Diego headquarters and Singapore site 15% In energy intensity (GJ/$M rev.) for total company 28% In landfill waste 15% In energy intensity for global manufacturing production Environmental targets Horizon 1 Divert packaging waste from landfill by 2023 • • • Social ResMed Foundation -Approved $250K in community grants to local San Diego philanthropies - Contributed to ongoing clinical research and public awareness grants Recently raised funds for cancer research and furthering black education in the U.S. $1M+ donated annually to 150+ community organizations and academic institutions. through our global sites in San Diego, Sydney, Lyon, Munich, and Singapore Reduce industrial waste, energy, and water usage Horizon 2 Divert product waste from landfill by 2026 Adopt low impact materials in both packaging and product by 2026 • Reduce material mass in packaging and product Horizon 3 • Products designed for circularity by 2030 • • · Governance Audit, Compensation, Compliance Oversight, and Nominating and Governance Committees 50% of independent directors are women, 38% of board directors are women Top 4% for S&P 500 companies for gender diversity on board Recognized by others for leading in this space: #15 in Healthcare & Life Sciences, #106 on Newsweek's 2021 "America's Most Responsible Companies" # 18 in Healthcare & Life Sciences, #105 on WSJ's 2020 "Management Top 250" • Canada's Top 100 Employers for 2021, Australia's Top 5 Employers for 2021 "Just 100" Forbes; 2020 AMERICA'S MOST WSJ MANAGEMENT 2021 RESPONSIBLE Newsweek COMPANIES statista TOP 250 Canada's Top 100 Employers 2021 © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 10#11Experienced and diversified Board of Directors Carol Burt, BBA Principal of Burt-Hillard Investments; Former SVP of Corporate Finance and Development at Anthem Jan De Witte, MSE, MBA Former CEO of Barco Karen Drexler, BSE, MBA Former CEO of Sandstone Diagnostics; Advisor to the CEO of Hygieia Michael Farrell, BE, SM, MBA CEO of ResMed Diversified areas of expertise International 100% Strategy Healthcare Technology Public company executive 63% 75% 88% 88% 63 Years Average age 11 Years Average tenure Peter Farrell, PhD, DSC, AM Founder and Chairman of ResMed Harjit Gill, BA CEO of Asia Pacific Medical Technology Association Richard Sulpizio, BA, MS Former President and COO of Qualcomm Ronald Taylor, MA Lead Director Founder and former Chairman, President and CEO of Pyxis 38% Gender diversity 75% Independent O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 11#12Experienced leadership team focused on execution Michael "Mick" Farrell Chief Executive Officer Joined: 2000 Rob Douglas President and Chief Operating Officer 2001 Jim Hollingshead President, Sleep and Respiratory Care Business 2010 Bobby Ghoshal President, SaaS; Chief Technology Officer 2012 Justin Leong President, Asia and Latin America 2013 Katrin Pucknat President, ResMed Germany 2010 Brett Sandercock Chief Financial Officer 1998 David Pendarvis Chief Administrative Officer, Global General Andrew Price President, Global Operations © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Counsel 2002 1999 Vered Keisar Chief People Officer 2012 Hemanth Reddy Chief Strategy Officer 2013 Carlos Nunez, M.D. Chief Medical Officer 2017 12#13Well-positioned to improve quality of life and transform healthcare Healthcare spending as a percentage of GDP is expanding ResMed digital health assets can lower long-term cost of care and chronic disease progression Shifting mindset of plan providers: focus on long-term total cost of care Poor respiratory health driven by air quality issues in developing economies Chronic health issues driven by aging populations in industrial economies Our leading position in sleep and respiratory data is a key advantage toward this accelerating dynamic Our global footprint and recognized leadership in respiratory care enable us to address health crisis issues Evidence identified / supported by our data- rich ecosystem helps to proactively treat chronic conditions and improve quality of life Leveraging our leadership position and capabilities to improve the lives of ~1.6B people with undiagnosed sleep apnea, COPD, or asthma 936M with sleep apnea 380M with COPD 330M with asthma © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 ResMed technology improves outcomes and patients' lives 13#14Global Corporate Strategy Hemanth Reddy, Chief Strategy Officer ResMed#15ResMed 2025 | Patient-centric, digitally-enabled strategy ResMed 2025 250 million lives improved in out-of-hospital healthcare in 2025! Purpose Empower people to live happier, healthier, and higher quality lives in the comfort of their home Growth Focus Growth Advantage • Global health epidemics in sleep apnea, COPD, other major chronic conditions, and SaaS solutions that improve care in out-of-hospital settings Transform care through innovative solutions and tech-driven integrated care to drive superior outcomes, experiences, and efficiency Growth Foundations • High-performing, diverse, and entrepreneurial people Industry-leading innovation and business excellence • Digital health technology and scientific leadership O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 사 15#16Positioned to win Growing the market through commercial excellence and expanding market access Driving digital innovation in sleep and respiratory care to radically improve patient experience and outcomes Transforming out-of-hospital care at scale to drive better outcomes, lower costs, and improve quality of life O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 16#17Growing the market through commercial excellence and expanding market access Continuing to drive growth in our core channels Driving commercial innovation in new channels and through partnerships Generating clinical and economic evidence in sleep apnea and COPD and asthma © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Strong history of market development and growth 17#18Growing the market through new channels and partnerships New channel Joint venture . . ResMed × CVSHealth. Work closely with CVS to create streamlined sleep apnea patient journey in Health HUB locations where patients can be screened, assessed, and setup on therapy as well as purchase related products all within the CVS ecosystem Educate CVS pharmacy colleagues, care concierge, and center of excellence team members; provide input into digital efforts to effectively identify presence of sleep apnea and provide recommendations for further testing as necessary . . ● ResMed X verily = PRIMASUN Develop software solutions to identify, engage, and enroll individuals suffering from sleep apnea and other sleep- related disorders - guide them to get diagnosed and successfully treated Participate in the ecosystem of Verily companies to access sleep apnea patients and help them get diagnosed and treated Generate further evidence of the positive impact of sleep apnea treatment on other chronic health conditions © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Expanding our ability to reach and serve patients 18#19Unlocking markets and expanding access with evidence and advocacy Diverse evidence generating capabilities Solid foundation of clinical trials Economics and outcomes for value- based decisions ResMed Evidence Generation Team Behavior and population health research 1KOLS: Key opinion leaders Real world evidence studies with KOLs1 © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 1,096 Established scientific leader # of publications from 1996 onward 484 269 ResMed Peer 1 Peer 2 Better access and advocacy Unlocking reimbursement U.S. Competitive Bidding Program delay and removal of NIV from the program Supporting the creation of new U.S. physician remote monitoring codes On-time device reimbursement in key markets Thought leadership • Achieved leadership positions in key global MedTech associations Thought leader in European and member state health data policy and remote monitoring reimbursement conversations Engagement on key policies. • Health Technology Assessments (e.g., UK NICE) Analyses of French health insurance data to demonstrate the positive impact of CPAP therapy on lowering mortality rates Strong history of market development and growth 19#20Driving digital innovation across Sleep and Respiratory Care Well-positioned to drive digital innovation with... Market-leading connected therapies and unique suite of software solutions ↑ ↑ ↑ Leveraging our device and software capabilities to increase patient engagement and success with therapy Driving greater provider efficiency and effectiveness to increase patient adherence and lower labor intensity Uniquely positioned to deliver value through our software solutions given access to rich and proprietary data from our connected devices Where we are going Building on our established leadership position to drive more streamlined and integrated experiences through digitally powered integrated care models Leveraging our leadership position to transform Sleep and Respiratory Care O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 20#21Transforming care by enabling an integrated healthcare model Customer(s) Patients Payers Sleep apnea patient journey Integrated patient journey Identification Diagnosis Treatment set-up Healthcare providers Benefits Patients Payers Short-term adherence Resupply Long-term adherence Disease management Billing & Collecting Services + Treatment Data 000 Software Machine learning & analytics Reach and engage untreated patients Enable seamless patient experience Provide better care coordination Drive greater customer preference for ResMed solutions and brand Enable new care models Driving digital innovation across all aspects of the patient journey © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 21#22Transforming out-of-hospital care at scale Unparalleled scale and market presence Leading portfolio of software solutions to manage patients in OOH settings >105M lives improved through our SaaS solutions MatrixCare powers care for >250,000 patients a day Transforming out-of-hospital care Combining our software solutions (Brightree and MatrixCare) with our connected therapies and digital platforms to generate rich data sets and insights Leveraging our assets and capabilities to create more seamless transitions across multiple care settings Continuing to build our SaaS capabilities and increase our scale through strategic tuck-in acquisitions, new channels, and partnerships Brightree is used by >50% of HMEs that use commercially available electronic management systems brightree MatrixCare by ResMed by ResMed Driving better outcomes, lowering costs, and improving quality of life © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 22#23Sustainable growth driven by our flywheel Data sets Insights O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Patient access Focus on interoperability, privacy, and cybersecurity Utilize AI/ML to create world-leading data analytics platform Leverage strengths to increase access Patient quality of life Strengthen preference with patients and partners Develop, tailor, and commercialize world-leading therapies Continuously and more effectively help patients Brand preference Improve outcomes for patients, providers, and payors Better outcomes care solutions Integrated Identify, engage, and manage patients 23#24M&A is an accelerator of our strategy Ce Strategic intent 5 GU Portfolio enhancement Geographic expansion Added capabilities and technology Market development O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - K Strengthen competitive position 24#25Global Corporate Strategy | Key takeaways O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Positioned to continue winning in large, underserved respiratory medical markets with a patient-centric approach, unique ResMedian culture, and 30+ years of cutting-edge innovation 2 Leading the market in digital health - continue to disrupt and reinvent the medical device industry with cloud-connected devices, market-leading software solutions, and innovative analytics 3 Transforming out-of-hospital care at scale leveraging integrated healthcare models and partnerships to provide top-quality care at lower-acuity and people-friendly environments 4 Executing ResMed 2025 strategy to improve 250 million lives in out-of-hospital care by helping people breathe better, sleep better, and live better lives: all driving stakeholder value 25#26Pioneering the Future of Sleep Jim Hollingshead, President of Sleep and Respiratory Care ResMed#27Sleep and Respiratory Care (SRC) | Key messages O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Leading market position to capture massive total addressable market for treatment of disordered sleep, COPD, asthma, and related diseases 2 Unique capability to improve the patient's experience of therapy and outcomes through the integration of device therapy and digital solutions. 3 Established reputation for reinventing the industry fuels our flywheel business and further leads to brand preference, patient access, and data to unlock insights and improve outcomes 27#28Sleep and Respiratory Care snapshot $2.8B FY 2021 revenue Europe, Asia, and Other 140+ Countries 16.5M+ Patients in AirView FY 2021 SRC revenue by region 40% O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 9B + Nights of data FY 2021 SRC revenue by product 43% U.S., Canada, Masks & and Latin Other America 60% Devices 57% 28#29Proactive care to capture significant underpenetrated markets • Chronic disease is the largest driver of healthcare spending in developed economies Sleep apnea Leading indicator, and a contributing factor, to many chronic illnesses More than 80% undiagnosed Demonstrated positive dose-response relationship between CPAP usage and lower healthcare costs • • • COPD Largely undiagnosed COPD sufferers in high-growth markets such as China, India, Brazil, and E. Europe >100M Acute treatment costs to healthcare systems are large Europe: €48B per year - U.S.: ~$50B per year More than 3M people worldwide die each year due to COPD Asthma Significant opportunity to improve adherence and improve patient-physician interaction Leveraging Propeller for increased data related to symptom occurrence and acute triggers Opportunity to partner with patients, providers, pharmaceutical companies, and payors to drive improved quality of life 936M sleep apnea patients Total addressable market 380M COPD patients 330M asthma patients Well-positioned to expand proactive treatment of chronic diseases 1World Health Organization. The top 10 causes of death: Fact sheet: No310 (2014, May) accessed 20Jul16 2 https://www.ncbi.nlm.nih.gov/pubmed/26755942 3 Company estimates based on World Health Organization estimates and Zhong et al. "Prevalence of Chronic Obstructive Pulmonary Disease in China" Respiratory and Critical Care 4 European Respiratory Society, European Lung White Book http://www.erswhitebook.org/chapters/the-economic-burden-of-lung-disease/accessed 20 Jul16 5 Guarascio et al. Dove Med Press, 2013 Jun 17 6 World Health Organization. Chronic obstructive pulmonary disease (COPD): Fact sheet No315. 2015 accessed 20Jul16 © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 29#30Sleep and Respiratory Care | Sustainable competitive advantages Industry pioneer with leading IP portfolio and "trade secret" knowledge base Established reputation in core channels; growing with new channels and partners Largest installed base and most-used platform by patients and providers Largest sleep database with 9B+ nights of sleep data Unique ability to deploy device therapy integrated with AI/ML data solutions The best people, using world-class processes Leveraging our long-standing industry leadership to drive the future of chronic respiratory therapy O 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 30#31Positioned to win Growing the market as the premier developer and innovator of sleep and respiratory care solutions Driving digital innovation to create a better patient experience, lower overall healthcare costs, and create better outcomes Leveraging our scale to drive better outcomes, lower costs, and improve quality of life O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 31#32Nasal Full Face Leadership in OSA treatment with physical devices Latest launch Resid AirSense™ 11 MoMed 虎 Devices AirMini™ 90 RosMed AirSense™ 10 AirCurve™ 10 Key differentiators Quietest, most intuitive devices on the market AirSense 11: newest, most connected device Expanding digital tools for patient experience, including patient engagement built into device • Minimalist Masks1 Freedom Universal Fit Ultra Soft AirFit™ F30 AirFit™ F30i AirTouch™ F20 AirFit™ F20 AirFit™ P10 AirFit™ N30 AirFit™ N30i AirFit™ P30i AirTouch™ N20 AirFit™ N20 1Curent in-line masks being promoted; not an exhaustive list © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - ✓ Premium comfort and machine-agnostic masks; widest range of masks on the market meeting the broadest set of patient needs Largest database of facial features; focused on designing for fit Expertise and experience in translating clinical knowledge into product features (e.g., comfort, durability) 32#33Leadership in OSA treatment with data applications ResMed myAir TM whipp Alanine and ancroid Realwed Продт day June 18- 91 kva Title 204 0 & Key differentiators AirView™ ResMed ResMed ResMed AirSION ResMed 2014. Eugene, Judy Las ResMad AirNew Patients Training for HME Training for Sleep Lab Main Men Heme User-friendly, intuitive platform provides milestone accomplishments and motivation to patients, increasing therapy adherence, and improving sleep quality Focused on app enhancements to enable long-term adherence for life vs. short-term (e.g., app-based nudges) Clear-cut market leader with 3.5M U.S. patients registered to the myAir platform across the website and app Recently launched upgraded version: myAir 2.0 © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Large installed base with over 16.5M patient enrolled in our cloud-based software solution Seamless integration with ResMed devices enhances provider efficiency and improves patient monitoring through industry-leading remote diagnostic tools Increased data capture enables us to drive more personalized care to improve the patient experience Unlocking value for both patients and providers 33#34At the forefront of Respiratory Care Patient Management Pesed Aw Ventration patients wwwww Pace: Jimmy AirView™ for Ventilation Bilevel Ventilation Digital Therapeutics Duty code Propeller Non-invasive Ventilation (NIV) Raked High-Flow Therapy Realled AcuCare™ HFNC Lumis High flow nasal cannula HFT Life Support Ventilation Highlights Widest range of therapies for higher acuity respiratory patients, including COPD and asthma TM Broadest set of digitally connected respiratory therapy devices AirCurve™ 10 Lumis™ 100 Stellar™ 100 Astral™ Astral™ 150 Life support ventilator VPAP ST Patient Acuity Market leading platform for managing inhaled medications Premier solution for remote management of ventilated patients O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - The right device, for the right patient, at the right time 34#35ResMed device market share Q3FY14 Q4FY14 Q1FY15 Q2FY15 Q3FY15 Q4FY15 1Estimate prior to competitor recall Shift to digitally-enabled treatment has fueled growth Q1FY16 Q2FY16 Q3FY16 Q4FY16 Q1FY17 Q2FY17 Device market share compared to AirView and myAir growth Q3FY17 Q4FY17 Q1FY18 AirView Q2FY18 Q3FY18 myAir Q4FY18 Q1FY19 Q2FY19 ResMed Q3FY19 Q4FY19 Q1FY20 Q2FY20 Q3FY20 Q4FY20 Q1FY21 Q2FY21 Q3FY21 Q4FY21 16.5M+ AirView and myAir growth 3.5M+ Launches of new, digitally-enabled products have driven market growth, and increased patient adherence and market share gains Demonstrates ability to drive market growth with unique and innovative solutions Over time, we have shifted toward a tech-focused strategy vs. device-focused; future product launches to be driven by digital health © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 #1 market share1 in sleep apnea devices and masks 35#36Case Study | AirSense 11 demo The wait is over. We've launched! Introducing ResMed AirSense™ 11 backed by Air Solutions AirSense 11 11 ArSense 11 O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 36#37Data-driven future of therapy • • AirSense 11 is a two-way communication data platform - - - Both cell and Bluetooth connectivity Seamless pairing with myAir app and directly to the cloud Very rich consumer-like experience on myAir app Patient questions and prompts on the device Built for Over-the-Air (OTA) upgrades Add new features without new hardware Improved patient adherence Even more streamlined provider workflows and lower costs Improved patient management Home MY OPTIONS - Future: Patient Reported Outcomes Metrics (PROMs) for payors and health systems + MORE S AirSense™ 11 MY SLEEP VIEW ResMed MAX AirSense 11 is the device platform that will enable us to deploy AI/ML into sleep therapy O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 37#38Propeller's strong value proposition in Respiratory Care Value proposition Enables increased data capture and analysis Improves insight into patient adherence for physicians - - Current adherence rates as low as 20% in COPD treatment Studies show Propeller can increase adherence >58% Helps patients identify potential triggers of acute symptoms Seamlessly integrates the patient, physician, and their pharmacy; data flows between us and our partners to continuously improve the process - Proactive data-driven approach to COPD and asthma treatment can drastically reduce occurrence and associate costs of acute respiratory treatment 1Merchant, Rajan, et al. "Impact of a digital health intervention on asthma resource utilization." World Allergy Organization Journal 11.1 (2018): 28. ED: Emergency Department © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Events per 100 patients Reduced acute care utilization with Propeller1 13 12 CO 6 5 Pre-enrollment Post-enrollment 2 0 ED + Hosp. ED Hosp. Positive momentum in the market 38#39Leveraging our scale with data and digital solutions Now Next With more than 9 billion nights of therapy usage data we have a unique ability to create actionable insights: For Patients • Coaching and usage help in context through myAir app . For Providers • Patient management by exception, streamlined workflows, lower costs, higher adherence, and increased revenue For Payors • Increased patient adherence and improved ROI on therapy For Patients • Personalized coaching in myAir based on ML For Providers Patient management by prediction For Payors • Proof that it pays to find and treat sleep apnea patients; improved patient management with PROMS Benefitting all stakeholders with better outcomes and lower costs © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 39#40Sleep and Respiratory Care further accelerates the ResMed flywheel Data sets Insights O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Patient access Focus on interoperability, privacy, and cybersecurity Utilize AI/ML to create world-leading data analytics platform Leverage strengths to increase access Patient quality of life Strengthen preference with patients and partners Develop, tailor, and commercialize world-leading therapies Continuously and more effectively help patients Brand preference Improve outcomes for patients and payors Better outcomes care solutions Integrated Identify, engage, and manage patients 40#41Sleep and Respiratory Care further accelerates the ResMed flywheel Lower costs Data sets More patients Patient access Better patient experience Insights care solutions Integrated High market share Improved outcomes O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Brand preference More HME revenue Better outcomes ntify, engage, and enage patients 41#42Sleep and Respiratory Care | Key takeaways Q 1 Leading market position to capture massive total addressable market for treatment of disordered sleep, COPD, asthma, and related diseases O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 2 Unique capability to improve the patient's experience of therapy and outcomes through the integration of device therapy and digital solutions. 3 Established reputation for reinventing the industry fuels our flywheel business and further leads to brand preference, patient access, and data to unlock insights and improve outcomes 42#43Software as a Service (SaaS) Bobby Ghoshal | President, SaaS and Chief Technology Officer ResMed#44SaaS | Key messages O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Leading provider of SaaS solutions providing mission critical software across a broad set of attractive markets in out-of-hospital (OOH) care 2 Differentiated value creation within the SaaS portfolio through our breadth and commitment to innovation, as well as opportunities with the ResMed Sleep and Respiratory Care business 3 Positioned for sustainable growth through innovation, commercial excellence, partnerships and M&A 44#45We focus on software and services for out-of-hospital care providers Our breadth uniquely positions us to be the innovation engine for providers Out-of-hospital care ecosystem Software solutions and data Home Medical Equipment Providers brightree by ResMed MatrixCare® by ResMed 0 0 0 Pharmacy/ Infusion Home Health Hospice/ Palliative Care Private Duty Skilled Nursing Senior Living © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 We are the gateway to out-of-hospital care Life Plan Communities 45#46We have a leading position across these markets PATIENT & RESIDENT RECORDS API CALLS & OTHER TRANSACTIONS USERS 105M+ 10M+ 700K+ Continuously expanding market potential IN OUR OUT-OF-HOSPITAL PER DAY CARE NETWORK ✓ HME: #1 position and expanding into Pharmacy / Home Infusion ✓ Home Health & Hospice - Large: 2020 Best in KLAS Award Home Health - Large: 2021 Best in KLAS Award ✓ Skilled Nursing Facility: Multi-year winner of Best in KLAS Award - $2.0B FY 2021 estimated market size $374M FY 2021 ResMed SaaS revenue One of the leading market positions across the markets we serve – with room to grow O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 46#47Relentless focus on software functionality ^ ^ ^ ^ ^ Mission critical software for care provider operations including business management and electronic health records Best-in-class clinical functionality as we provide automated clinical workflows and enable clinicians to have an end-to-end view of patient care Breadth of solutions gets richer every year by extensively building, buying, and partnering for our customers Rich data assets that power AI/ML-driven functionality such as adverse event prediction (like falls) Comprehensive set of healthcare interoperability modalities designed to meet the needs of our OOH care providers and other stakeholders © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Powerful software platforms enabling interoperability 47#48Markets are supported by structural tailwinds... ...but patients and providers face significant unmet needs Tailwinds Aging population and chronic conditions Rising healthcare costs Pressure to reduce overall acute care spend > Regulatory Unmet needs changes to payment models and policies Shortage of caregivers > Lack of visibility across care settings/ care transitions Drives increasing long-term care needs Move towards value-based care $$ Patients being transitioned out of hospital to lower-cost settings $ Creates administrative burden and complexity for care providers Requires technology to deliver smarter solutions that improve efficiencies and outcomes Creates need for coordination across care providers © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 48#49Uniquely positioned to address provider needs brightree by ResMed MatrixCare by ResMed Demand for greater coordination across provider markets . 000 0 0 0 Home Medical Equipment Providers Pharmacy/Infusion Home Health Hospice/ Palliative Care Private Duty Skilled Nursing Senior Living Life Plan Communities . Providers are diversifying and lines are blurring across the continuum; Skilled nursing facility owners are moving into home-based care We are working with our customers to address their needs, holistically across the markets they serve . Our solutions are supported by the richness of our data O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 49#50Uniquely positioned to serve ResMed patients with resupply Robust suite of solutions to simplify and optimize a complex process Integrates with ResMed Air Solutions to streamline further brightree by ResMed ResMed through automation Setup Billing Insurance Verification Prep Equip for Setup Training & troubleshooting Payer Billing Enables HMEs to optimize resupply programs for eligible patients Scheduling Intake Compliance Referral Management Customer Service . Leveraging technology to diversify our resupply to other categories Supported by our richness of data Resupply Insurance & eligibility verification Dedicated resupply Customer Service Order Entry Resupply Outreach Complex Process Document Chase Fulfillment Billing Brightree: helping HME industry increase efficiency, serve patients, and drive core business © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 50#51Drivers of long-term value creation Our talented teams and culture ^^ Innovation & commercial excellence Accelerate growth with our proven M&A capabilities Investing in our business to drive long-term, profitable growth, accelerated by M&A © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 51#52Proven M&A capabilities M&A has been a priority and will continue to be a priority brightree by ResMed + Added Capabilities conduittechnology AllCall Connect Apacheta CORPORATION Mobile Business Solutions HEALTHCARE +first 2017 Enhanced HMES' custom forms and workflow solutions 2017 Provided live call center services for HMES 2018 Dispatch and fleet-management solution with a mobile proof-of-delivery application 2018 Software solutions to optimize clinical, financial, and administrative processes MatrixCare by ResMed SNAP 2020 Elevated Brightree's ReSupply platform, creating the largest CPAP resupply patient base CITUS 2021 HEALTH Digital health platform supporting care-team, patient and family caregiver collaboration needs. Focused on acquisitions that increase our breadth of offering and accelerate strategic capabilities © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 52#53SaaS | Key takeaways O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Leading provider of SaaS solutions providing mission critical software across a broad set of attractive markets in out-of-hospital care 2 Differentiated value creation within the SaaS portfolio through our breadth and commitment to innovation, as well as opportunities with the ResMed Sleep and Respiratory Care business 3 Positioned for sustainable growth through innovation, commercial excellence, partnerships and M&A 53#54Q&A ResMed#55BREAK ResMed#56Leadership in Digital Health Technology Bobby Ghoshal | President, SaaS and Chief Technology Officer ResMed#57Digital Health Technology | Key messages O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Transforming ResMed to a data-first organization and actively building next gen AI/ML driven products leveraging ResMed data assets on our world-class data platform 2 Accelerating pace of innovation by adopting native cloud technologies and patient-centric architecture 3 4 Launching new and innovative digital products to improve end-to-end patient and customer experience Investing in interoperability and integration capabilities for the premier digital health platform in our industry 57#58ResMed's purpose is attracting top talent to our Digital Health team World-class team of engineers, data scientist, and analysts working on our best-in-class data platform +4x Data Scientists, Engineers Data scientists and engineers from leading technology and data-driven organizations PUT Massachusetts Institute of Technology MIT Partner attracting top notch students NQAQIDAQQ O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 58#59Unparalleled scale today with future exponential growth Over the past 3 years, we have grown... 5x Nights of sleep 7x API calls per second 2x AirView patients 2.5x MyAir patients 2.5x 4x MyAir daily sign-ups Remote patient settings changed O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Deep breadth of technology across the globe 70+ Variety of devices 140+ Countries with patients using ResMed devices 430+ Carriers supported by ResMed technology 59#60A data-centric enterprise We are building muscles around data, insights, and analysis across the entire enterprise 0.0 SUPPLIER PLANNING MANUFACTURING DISTRIBUTION MARKETING SALES SUPPORT UTILIZATION Empowering teams with the data they need to further unlock efficiencies © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 60#61Data product example: patient adherence (90-day compliance) AirView data MyAir data OOH (SaaS) data Data aggregation into ResMed data lake – data engineers Ideate, evaluate - data scientists, analysts, product management Data Science Analysis Data product example from our Sleep and RC business Build - intelligence layer ML engineers, data scientists Feedback loop - Implement application layer software engineers, product management Experiment / iterate O my Airfor Air10 by ResMed ResMed ResMed AirView 85 Sleep Lab MyAir app AirView • • Data is fed into our data lake every 4 hours Power of 9B+ nights of sleep data Hypothesis-driven analysis / data science Use data to predict patient behavior and develop actionable insights to keep patient engaged with therapy Use myAir, AirView platforms to interact with patients and improve sleep quality with nudges and optimization algorithms Improve patient adherence to therapy © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Driving personalization at scale 61#62Architecture transformation Transformation to cloud native Dramatic reduction of time to market for our apps from several weeks to a few days 1FHIR: Fast Healthcare Interoperability Resources O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 0 B Patient data security and privacy ون Patient-centric solutions Incorporating industry favored FHIR1 standards for interop and integration 62#63World's leading digital health platform AirView APPS/DIGITAL THERAPEUTICS DEVICES ResMed ecosystem Connected devices and digital health Propeller PATIENT/ CONSUMER myAir CLINICIAN IDN Out-of-hospital platform brightree by ResMed >> Artificial intelligence Patient outcomes MatrixCare Machine learning by ResMed HME/PAYORS HEALTHCARE first by ResMed >> Focused on interoperability so our ecosystem works with the broader healthcare ecosystem © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Business outcomes Operations 63#64Digital Health Technology | Key takeaways O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Transforming ResMed to a data-first organization and actively building next gen AI/ML driven products leveraging ResMed data assets on our world-class data platform 2 Accelerating pace of innovation by adopting native cloud technologies and patient-centric architecture 3 4 Launching new and innovative digital products to improve end-to-end patient and customer experience Investing in interoperability and integration capabilities for the premier digital health platform in our industry 64#65Driving Operational Excellence Rob Douglas, President and Chief Operating Officer ResMed#66Operational Excellence | Key messages C 1 Delivering a world-class patient experience inspires everything we do O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 2 3 Driving operational excellence across our businesses with a focus on innovative and digitally-enabled solutions Leveraging our scale, technology, and data to enable integrated care models, optimize global operations, and capitalize on changing healthcare economics 66#67Competitive advantages to accelerate operational excellence Unique, medically-focused culture with emphasis on quality of treatment Industry leader with strong reputation for innovation and quality Recognized, trusted data partner for systems and clients Expertise in collecting and analyzing complex clinical data • Substantial operational scale drives cost-leadership Strong supply chain providing high-quality products in volume Long-term performance driven by ResMedian culture of continuous improvement O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 67#68Focused on sustainability in our operations Continuously developing solutions to reduce waste and drive sustainability across our operations • Near to medium-term target of 100% recyclable materials Through life cycle assessment (LCA) model, product development teams consider environmental impact in raw materials, manufacturing logistics, product use, and eventual recycling / disposal Focused on improving environmental performance in packaging by reducing material mass, adopting low impact materials, and diverting product waste from landfill Using Sydney as a model for waste and energy reduction Sydney Innovation and Manufacturing center operates an Environmental Management System (EMS) certified to ISO 14001 with objectives to reduce CO2 emissions, waste consumption, and waste EMS will be progressively extended across ResMed's global network over the coming years Elevating sustainability across our global manufacturing operations Our Global Business Excellence Program includes sustainability as a dimension along with quality and financial performance to engage global team members to contribute to overall environmental performance O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 68#69O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - ResMed 69#70Leveraging our scale to enhance supply chain management Dublin, Halifax, Nova Ireland Lyon and Scotia Paris, France 43,000 ft² Chatsworth and Moreno Valley, California Munich, Germany 43,000 ft² 30,000 ft² & 71,000 ft² Atlanta, Georgia 466,000 ft² Manufacturing facility R&D facility Johor, Malaysia 46,000 ft² China 65,000 ft² Singapore 268,000 ft² Sydney, Australia 155,000 ft² Highlights Focused on supply chain risk management process Asia-based (ex-China) Diversified manufacturing locations, including U.S. Size and scale to navigate geopolitical hurdles and disruptions Unparalleled ability to serve global markets Ability to navigate evolving market situations with resilient and flexible global supply network © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 70#71Growing our global footprint with new factory in Singapore. ResMed Tan Highlights Signed 10-year lease with 2 10-year extensions ~258,000 ft² total floor area | Four floors with rooftop truck parking Large capacity capabilities Ability to optimize Singapore processes Successfully designed, implemented, and transferred to new factory Factory investment increases capacity capabilities and ability to optimize processes O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 71#72Increasing efficiency through automation in mask manufacturing Paolliks ResMe Restha ResMed Driving safety and efficiency in our world-leading mask operations © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 72#73Case Study | Ability to rapidly increase production capacity • Background / Need Needed to significantly increase Astral and Stellar production in response to critical global need for ventilators during COVID-19 To maintain production team, needed to minimize safety and infection risks - - - • ResMed solution Rapidly increased our labor capacity by: Implementing afternoon and night shifts Re-skilling team members from other areas of the factory (e.g., LSR) Developing a basic training program to up-skill 10 team members in 10 days Implemented rapid process changes - - Identified and implemented in less than 4 weeks; re-balanced activities across various production stations Reduced Astral and Stellar cycle times by more than 20% and 25%, respectively Outcomes ✓ Increased capacity by over 350% across both platforms ✓ NO COVID-19 infections or transmissions in the manufacturing center ✓ Produced over 20,000 critical care Astral and Stellar ventilators, contributing to more than 150,000 ResMed ventilators shipped Established procedures to reduce infections (e.g., team segregation, increased cleaning, reduced on-site personnel) Quickly enhanced internal processes to produce more critical products for our patients © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 73#74Global presence with ability to serve multiple market models Long-standing history serving customers Brightree enabled further penetration of markets Best-in-class therapy increases adherence and drives preference to ResMed Mainly in North European countries; government tenders for supply of sleep therapy Developed strong relationships during pandemic, driven by ResMed's unique ability to quickly fulfill large short-term orders 1HME: Home Medical Equipment; DME: Durable Medical Equipment Focused on healthcare in Germany HME /DME 1 Home care provider Business calling for referrals and billing insurance Government sales ResMed Retail locations in Australia Direct-to-Consumer Subscription clubs in non-reimbursed markets Continuing to penetrate different markets, while expanding the channels that we serve O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 74#75Continuing to build on strong channel relationships ResMed TALI Market situation Underpenetrated Australian market Lack of patient awareness for sleep apnea Higher patient responsibility for device costs vs. other markets ResMed solution Focused on new sales channels: distribution, retail stores, pharmacy, and ecommerce Enhanced market presence with "Awaken your best" campaign Created spa-like, consumer- driven retail experience 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Outcome Significantly changed the growth trajectory of the Australian sleep business Increased overall awareness of sleep apnea Improved market growth across all sales channels 75#76Continuous improvement mindset Standardized and codified strategic framework: OKR (Objectives and Key Results) process Each team has its own set of meaningful objectives and stretch goals that align with company-wide priorities; >160 teams using this framework across ResMed Engage ResMedians to Align priorities across teams Track our progress Drive transparency across the Company Implement near and long-term execution priorities to ensure continuous alignment with our ResMed 2025 growth strategy Further positioning our organization to execute on our 2025 strategy © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 76#77Operational Excellence | Key takeaways C 1 Delivering a world-class patient experience inspires everything we do O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 2 3 Driving operational excellence across our businesses with a focus on innovative and digitally-enabled solutions Leveraging our scale, technology, and data to enable integrated care models, optimize global operations, and capitalize on changing healthcare economics 77#78Financial Strategy Brett Sandercock | Chief Financial Officer ResMed#79Financial Strategy | Key messages O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Building on our strong track record of revenue growth with compelling future opportunities driven by accelerating adoption of digital health technologies for sleep apnea and COPD 2 Growing our portfolio of value-adding businesses and expanding recurring revenue in large markets 3 Driving operating margin expansion through revenue growth and SG&A leverage, while continuing to invest in R&D 4 Leveraging our strong cash flow and balance sheet for both organic and inorganic investments with a focus on driving long-term stakeholder value 79#80Strong track record of execution and shareholder returns $2.1 Revenue ($B) +12% CAGR $3.2 $3.0 $2.6 $2.3 Non-GAAP Operating Income ($M) Non-GAAP EPS & Margin +18% CAGR +17% CAGR $994 $891 $716 $3.53 $3.64 $607 $2.82 $508 31% 30% 25% 26% 27% $5.33 $4.76 FY 2017 FY 2018 FY 2019 FY 2020 FY2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 NOTE: see reconciliation to GAAP in Appendix. Total Shareholder Return (TSR) (NYSE shares as of 6/30/2021): 1-yr 29% | 3-yr 146% | 5-yr 318% O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 80#81Robust free cash flow generation Free cash flow generation ($M) +16% CAGR 5-year average: $505 $442 $390 $352 $707 $634 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 Highlights Consistently strong free cash flow generation Timing of working capital movements impacted FY 2019 and FY 2020 cash flows Positive cash conversion ratio Low capital intensity business Strong track record of generating recurring free cash flow 81#82Strong balance sheet with ample liquidity Summary balance sheet ($M, as of 6/30/2021) Cash and cash equivalents Total current assets SA Liquidity ($M, as of 6/30/2021) Available credit 295 SA 1,600 $ 1,575 Cash SA 295 Total assets SA $ 4,728 Total available liquidity $ 1,895 Total current liabilities $ 912 Total debt SA 655 Net debt 360 Total equity $ 2,886 . ● Recent increase in inventory driven by supply chain risk mitigation, shift of products to new factory, and the launch of AirSense11 Working capital remains a focus Debt levels remain modest; $1.6B available for drawdown under our existing revolver facility Low leverage and strong liquidity provide financial flexibility © 2021 ResMed | 2021 Investor Day - Sept 8, 2021 82#83Compounding impact from patient adherence Mask growth paradigm Growth Installed base New patients Automated ReSupply New products Increased long- term adherence Time Digital innovation has powered mask growth Long-term patient adherence results in increased recurring revenue Mask growth has improved over time: FY12-16 CAGR of 8% FY17-21 CAGR of 10% Focused on driving increased mask growth to drive recurring revenue © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 83#84Strategic capital allocation framework Capital deployed over last 3 years (through June 30, 2021) Higher priority 33% 1% $2.0B 36% ■ Reinvest in R&D ■ M&A ■ Dividends ■ Share repurchase 30% Lower priority Reinvest for growth Reinvest in product development for high-return organic growth 7% of FY 2021 revenue invested in R&D Pursue M&A Actively evaluate potential acquisitions Pursue targets aligned with long-term strategic goals and financial objectives Support dividends • Regular return of cash to shareholders through dividend at a level that is meaningful and sustained Opportunistically repurchase shares Opportunistic repurchase of shares Current program suspended following acquisitions of MatrixCare and Propeller © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Disciplined focus on ROIC and delivering total return 84#85Disciplined and strategic M&A approach Strategic intent GU Portfolio enhancement Geographic expansion Added capabilities and technology Market development Financial criteria Enhances revenue profile Attractive operating margin © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 Strengthen competitive position EPS accretion (typically, within 2 years) ROIC > WACC (within designated timeframe) 85#86Strong track record of M&A Our transformative acquisitions have enabled tuck-in opportunities, creating added capabilities brightree Added Capabilities by ResMed MatrixCare by ResMed Propeller conduittechnology AllCall Connect • Apacheta CORPORATION Mobile Business Solutions 2017 Enhanced HMES' custom forms and workflow solutions 2017 Provided live call center services for HMES 2018 Added mobile applications to automate and streamline HEALTHCARE +First SNAP CITUS HEALTH 2018 Software solutions to optimize clinical, financial, and administrative processes 2020 Elevated Brightree's ReSupply platform, creating the largest CPAP resupply patient base 2021 Enhanced real-time communication technology, specifically real-time response, to inbound communications ResMed Enhanced portfolio empower companies to business processes Proven ability to integrate and leverage transformative acquisitions and tuck-ins © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 86#87Long-term financial goals Meet or exceed annual market growth ranges Drive operating margin of 30%+ Increase recurring revenue Reinforce geographic diversity Market growth expectations: Devices Masks & Accessories Mid single-digit High single-digit SaaS Mid to high single-digit Driven by continued positive operating leverage and disciplined supply chain management Driven by improved patient adherence due to SaaS solutions and revenue growth from mask and device resupply Building a best-in-class global workforce and footprint ResMed plans to meet or beat market growth across all segments © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 87#88Financial Strategy | Key takeaways O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 1 Building on our strong track record of revenue growth with compelling future opportunities driven by accelerating adoption of digital health technologies for sleep apnea and COPD 2 Growing our portfolio of value-adding businesses and expanding recurring revenue in large markets 3 Driving operating margin expansion through revenue growth and SG&A leverage, while continuing to invest in R&D 4 Leveraging our strong cash flow and balance sheet for both organic and inorganic investments with a focus on driving long-term stakeholder value 88#89Closing Remarks Mick Farrell | Chief Executive Officer ResMed#90Investment summary 30+ years of cutting-edge innovation Uniquely positioned to win in massive, largely underserved markets with a patient-centric approach, and a strong ResMedian culture Leading in digital health as we continue to reinvent the industry through connected, cognitive solutions Transforming care at scale through the lens of integrated healthcare models and strategic partnerships Executing ResMed's 2025 strategy to improve 250M lives, drive sustainable growth, and create long-term stakeholder value Patient access Data sets Insights Focus on interoperability, privacy, and cybersecurity Utilize AI/ML to create world-leading data analytics platform Leverage strengths to increase access Patient quality of life Strengthen preference with patients and partners Brand preference Improve outcomes for patients and payors Develop, tailor, and commercialize world-leading therapies Continuously and more effectively help patients care solutions Integrated antify, engage, an manage patients O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - Better outcomes 90#91Q&A ResMed#92Appendix ResMed#93Speaker Biographies Mick Farrell Chief Executive Officer Michael "Mick" Farrell was appointed ResMed's CEO and has served as a director since March 2013. He joined the company in 2000, serving as president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and various senior roles in marketing and business development. Before joining ResMed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, DowDuPont, and BHP Billiton. Mick serves on the board of directors of ResMed, the Advanced Medical Technology Association (AdvaMed) and Zimmer Biomet (NYSE: ZBH), a multibillion-dollar public company that provides implantable musculoskeletal medical devices for patients globally. He is also a member of two committees at Zimmer Biomet: Nominating and Governance as well as Compensation and Management Development. He also volunteers as a trustee for non-profit organizations: UC San Diego Foundation, Rady Children's Hospital, and Father Joe's Villages in San Diego, California. Mick holds a bachelor of engineering with first-class honors from the University of New South Wales, a Master of Science in chemical engineering from the Massachusetts Institute of Technology, and a Master of Business Administration from the MIT Sloan School of Management. O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 93#94Speaker Biographies Hemanth Reddy Chief Strategy Officer Hemanth Reddy was appointed ResMed's chief strategy officer in September 2013, responsible for the company's global corporate strategy and corporate development functions. Prior to joining ResMed, Hemanth was a strategy consultant for 14 years, advising on a range of issues including corporate strategy, business unit strategy, portfolio strategy, and inorganic growth strategy across consumer products, high tech, biotech and other industries. He was most recently a principal with Monitor Deloitte, Deloitte Consulting's Strategy practice, co-leading its San Francisco office. Prior to Deloitte, he was a partner with Monitor Group where he co-led corporate finance activities in North America and shared leadership responsibility for Monitor's Mergers & Acquisitions advisory practice. Before Monitor Group, he was an investment banker with Donaldson, Lufkin & Jenrette (DLJ) in New York, where he advised clients in structuring and executing debt and equity offerings, as well as private equity transactions. Hemanth holds a Master of Business Administration in Finance, Strategy and Marketing from Northwestern University's Kellogg School of Management and a bachelor's in computer science from Cornell University's College of Engineering. O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 94#95Speaker Biographies Jim Hollingshead President, Sleep and Respiratory Care Business Jim Hollingshead was appointed president of ResMed's Sleep and Respiratory Care business in June 2020, an extension of his role as president of Sleep, which he's held since July 2017. He previously served as president of the company's Americas region, beginning in March 2013. He joined the company in 2010 as vice president of Strategy and Business Development. In 2011, his role was expanded to include the leadership of ResMed's Ventures and Initiatives unit, responsible for growing early-stage businesses. An industry leader in digital health, Jim helped create and execute ResMed's strategy to transform its business - and the sleep therapy industry - by introducing built-in communications on all of its sleep apnea devices, coupled with cloud-based business process automation applications that help customers grow revenues while also cutting costs. Under Jim's leadership in the Americas region, ResMed launched the Air10 TM Series of cloud-connected CPAP machines, which led to rapid share gains and unprecedented adoption of its SaaS platforms. As a result, ResMed is the world leader in CPAP machines and masks, with an expanding portfolio of sleep and respiratory care device- and SaaS-based offerings for both patients and healthcare providers. Before joining ResMed, Jim spent 18 years in strategy consulting, where he worked with senior executives across a wide range of industries, mainly biotech, high tech and telecommunications. From 2008 to 2010, he was a senior partner in the Strategy and Life Sciences practices at Deloitte Consulting, based in San Francisco. Before that, Jim was West Coast managing partner for Monitor Group, a leading global strategy consulting firm, working in various offices around the world and successfully launching and running three different practices, including a London-based pan-European marketing strategy practice. Jim currently sits on the boards of Insulet (NASDAQ: PODD), the global leader in digital diabetes health and tubeless insulin pump technology; the Medical Device Innovation Consortium (MDIC), a public-private partnership aiming to improve patient access to medical technologies through regulatory science; and SleepScore Labs, a venture-backed startup that uses ResMed's proprietary sleep sensing technology to help validate and deploy a wide range of solutions that improve sleep. He's also a member of the executive steering committee of ResMed's joint venture with Verily, created to enable healthcare providers to more efficiently identify, diagnose, treat, and manage individuals with sleep apnea. Jim holds a Bachelor of Arts in history and international relations with Highest Distinction from Stanford University, and a master's and Ph.D in political science from the University of California at Berkeley, where he was awarded a graduate student Fellowship by the National Science Foundation. © 2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 95#96Speaker Biographies Bobby Ghoshal President, SaaS and Chief Technology Officer Bobby Ghoshal was appointed as chief technology officer (CTO) for ResMed in April 2018. He previously served as chief operating officer for Brightree, a ResMed-owned provider of cloud-based software-as-a-service for out-of-hospital care: delivering improved clinical and business performance for homecare customers. Prior to that Bobby led the information technology function for the US, Canada, and Latin America commercial teams, driving adoption of digital platforms and data analytics across the enterprise. Bobby has more than 25 years' experience in technology across multiple industries including finance, semiconductors and healthcare, working for companies including Freescale Semiconductor, Motorola, Compuware and Wipro Infotech. Bobby has helped build and lead high-performance teams in information technology, semiconductor innovation, digital and business strategy, information security, advanced analytics, operations and customer care. Bobby holds a Master of Business Administration degree from Arizona State University and a bachelor's degree in electronics engineering and telecommunications from the National Institute of Technology (NIT) in Calicut, India. O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 96#97Speaker Biographies Rob Douglas President and Chief Operating Officer Robert Douglas was appointed ResMed's president in March 2013 and chief operating officer in September 2011; together with ResMed chief executive officer, Mick Farrell, he holds full operational responsibility for ResMed and its subsidiaries. Previously, Rob was ResMed's chief operating officer of Asia Pacific and global supply chain from 2008 through 2011, responsible for the region's commercial distribution, sales operations, and global manufacturing; Sydney chief operating officer from 2005 through 2008, responsible for the company's manufacturing and research and development; vice president of operations from 2003 to 2005, responsible for the company's manufacturing; vice president of ResMed's respiratory and cardiac business from 2002 to 2003; and vice president of corporate marketing when he joined ResMed in 2001. Rob serves on the board of directors of Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, since December 2019, and is a member of the Audit Committee. He also serves as co-vice chairman on the Board of Directors of the San Diego Regional Economic Development Corporation, as well as vice chairman on the Board of Directors of EvoNexus, non-profit technology incubator. Rob has a Master of Business Administration from Macquarie University, a bachelor's in electrical engineering with first-class. honors, and a Bachelor of Science in computer sciences from the University of New South Wales, Sydney. a O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 97#98Speaker Biographies Brett Sandercock Chief Financial Officer Brett Sandercock was appointed chief financial officer in January 2006. Previously, he served as ResMed's vice president of treasury and finance from November 2004 until December 2005, and group accountant and controller from 1998 to 2004. Before joining ResMed, Mr. Sandercock was manager of financial accounting and group reporting at Norton Abrasives, a division of Saint-Gobain, a French multinational corporation, from 1996 to 1998. He also held finance and accounting roles from 1994 to 1996 at Health Care of Australia, a large private hospital operator. From 1989 to 1994, he worked at Pricewaterhouse Coopers in Sydney, specializing in audits of clients across distribution and manufacturing, financial services, technology, and other industries. From June 2019 to August 2021, Mr. Sandercock served as non-executive chair of the board of directors of Osteopore Limited (ASX:OSX), an Australian and Singapore based medical technology company, commercializing products used for the regeneration of bone across a range of therapeutic areas. Mr. Sandercock holds a Bachelor degree in economics from Macquarie University in Sydney, and is a certified chartered accountant. O2021 ResMed | 2021 Investor Day – Sept 8, 2021 - 98